Ischemic stroke
Conditions
Interventions
Control group:Clopidogrel+Aspirin
Experimental group:Cilostazol +aspirin
Sponsors
Affiliated Hospital of Guangdong Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. 18 = Age<80 years old, gender not limited; 2. Clinical and imaging (CT and MRI), except for cerebral hemorrhage or space occupying lesions; 3. (1) Non cardiogenic acute cerebral infarction with onset time less than 24 hours and NIHSS score = 5 points; (2) Patients who have not received intravenous thrombolysis and/or mechanical thrombectomy; 4. First onset or previous stroke without significant sequelae (mRS = 1); 5.Understand and sign the informed consent form
Exclusion criteria
Exclusion criteria: 1) Coma (patients with NIHSS 1a consciousness level score>1); 2) Moderate to severe stroke symptoms (NIHSS>6 points); 3) Pseudo medullary paralysis with swallowing difficulties; 4) Intracranial hemorrhagic diseases seen on head CT: cerebral hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural or epidural hematoma; 5) History of cerebral hemorrhage, subarachnoid hemorrhage, cerebral arteriovenous malformation or cerebral aneurysm, or brain tumor in the past; 6) The following serious internal medicine complications: uncontrolled hypertension, consistently above 200/110mmHg; Severe liver disease (ALT or AST>2 times the upper limit of normal, or total bilirubin>20mmol/L, or acute hepatitis, chronic active hepatitis, cirrhosis); Severe kidney disease (renal insufficiency) 7) Contraindications for clopidogrel, cilostazol, or aspirin: including allergies, severe renal or liver dysfunction, history of thrombocytopenia or platelet count<100 x10 9/L, history of coagulation disorders or systemic bleeding disorders; 8) Patients with cardiogenic ischemic stroke, or those currently taking anticoagulant drugs and requiring anticoagulant therapy during the study period; 9) Gastrointestinal bleeding, urinary system bleeding, or major surgical procedures in the past 3 months; 10) Pregnant or lactating women, as well as those planning to become pregnant during the entire trial period and women in their menstrual cycle; 11) Individuals with mental symptoms who are unable to cooperate; 12) Have participated in other clinical trials within 30 days prior to the date of obtaining informed consent, or are currently participating in other clinical trials; 13) Other researchers believe that it is not suitable to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of new stroke events (ischemic or hemorrhagic) occurring within 3 months; | — |
Secondary
| Measure | Time frame |
|---|---|
| The proportion of patients with good neurological function prognosis (mRS 0-1) after 3 months;3-month EQ-VAS scale score;3-month BI Score;Proportion of early neurological function improvement (NIHSS score reduction = 2 points) within 48 hours;Proportion of early neurological function improvement (NIHSS score increase = 4 points) within 48 hours; | — |
Countries
China
Contacts
Public ContactZhong Wangtao
Affiliated Hospital of Guangdong Medical University
Outcome results
None listed